Crizotinib: Uses, Side Effects & Warnings

• Crizotinib is a targeted therapy for specific types of non-small cell lung cancer (NSCLC) driven by ALK, ROS1, or MET exon 14 skipping mutations.
• It works by inhibiting specific tyrosine kinases, thereby blocking cancer cell growth and survival pathways.
• Common side effects include visual disturbances, nausea, diarrhea, and swelling, while serious risks involve liver problems, lung inflammation, and heart issues.
• Regular monitoring of liver function, vision, and heart activity is crucial during treatment.
• Patients must report any new or worsening symptoms to their healthcare provider promptly to manage potential adverse reactions.

What is Crizotinib Medication For?

Crizotinib is an oral medication classified as an anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor. It is specifically approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are positive for ALK or ROS1 rearrangements, or for those with metastatic NSCLC whose tumors have MET exon 14 skipping alterations. These genetic alterations lead to the production of abnormal proteins that drive uncontrolled cancer cell growth, making them ideal targets for Crizotinib’s mechanism of action.

The primary Crizotinib uses and indications revolve around its ability to selectively inhibit these mutated kinases. By blocking the activity of ALK, ROS1, and MET, Crizotinib can effectively slow or stop the proliferation of cancer cells and, in many cases, lead to tumor shrinkage. This targeted approach significantly improves outcomes for patients with these specific genetic markers, who historically had limited treatment options. Clinical trials have demonstrated notable response rates and progression-free survival benefits in these patient populations, establishing Crizotinib as a foundational therapy in precision oncology.

Beyond its initial approval, ongoing research continues to explore other potential applications for Crizotinib in various cancers that exhibit similar genetic drivers. For instance, studies have investigated its efficacy in other solid tumors with ALK or ROS1 fusions, as well as in certain types of lymphoma. The identification of specific biomarkers through genetic testing is paramount before initiating Crizotinib therapy, ensuring that the medication is prescribed to patients who are most likely to benefit from its targeted action.

Common Side Effects of Crizotinib

Like all medications, Crizotinib can cause side effects, ranging from mild to severe. Understanding these potential reactions is crucial for patients to manage their treatment effectively and report any concerns to their healthcare provider. The Crizotinib common side effects often involve gastrointestinal issues, visual disturbances, and fluid retention. These are generally manageable but can impact a patient’s quality of life if not addressed.

Many patients experience gastrointestinal symptoms such as nausea, diarrhea, vomiting, and constipation. These can often be mitigated with supportive care, including anti-nausea medications and dietary adjustments. Visual disturbances are also frequently reported, including blurred vision, flashes of light, or sensitivity to light. While usually mild, these symptoms warrant attention and should be discussed with an ophthalmologist if persistent or severe. Peripheral edema, or swelling in the hands, feet, and ankles, is another common occurrence due to fluid retention.

In addition to these, other frequent Crizotinib adverse reactions include fatigue, decreased appetite, dizziness, and changes in liver enzyme levels, which are typically monitored through regular blood tests. It is important for patients to communicate any new or worsening symptoms to their medical team, as timely intervention can often prevent these side effects from escalating. For example, persistent diarrhea can lead to dehydration and electrolyte imbalances if not managed promptly.

Here is a list of some of the most frequently reported common side effects:

• Nausea and Vomiting
• Diarrhea or Constipation
• Visual Disturbances (e.g., blurred vision, double vision, light sensitivity)
• Peripheral Edema (swelling in extremities)
• Fatigue
• Decreased Appetite
• Dizziness
• Abdominal Pain
• Changes in Liver Function Tests (often asymptomatic)

Crizotinib Warnings and Precautions

While Crizotinib offers significant benefits for eligible patients, it is associated with several important warnings and precautions that necessitate careful monitoring and patient education. These Crizotinib warnings and precautions are critical for ensuring patient safety and optimizing treatment outcomes. Healthcare providers must assess patients for pre-existing conditions and monitor them closely throughout the course of therapy for potential serious adverse events.

Hepatic Toxicity

One of the most significant warnings associated with Crizotinib is the potential for severe, life-threatening, or fatal hepatotoxicity (liver damage). Patients should undergo regular liver function tests, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, at baseline and at least every two weeks for the first two months of treatment, and then monthly or as clinically indicated. Any significant elevation in liver enzymes may require dose interruption, reduction, or permanent discontinuation of Crizotinib. Patients should be advised to report symptoms such as unexplained nausea, vomiting, abdominal pain, fatigue, dark urine, or yellowing of the skin or eyes immediately.

Interstitial Lung Disease (ILD) / Pneumonitis

Crizotinib treatment has been associated with severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis. The incidence of severe ILD/pneumonitis in clinical trials was low, but its potential severity makes it a critical concern. Patients presenting with new or worsening respiratory symptoms such as dyspnea (shortness of breath), cough, or fever should be promptly evaluated for ILD/pneumonitis. If ILD/pneumonitis is suspected, Crizotinib should be withheld, and if confirmed, it should be permanently discontinued. Early detection and management are vital to prevent severe complications.

Cardiac Effects and Visual Disturbances

Crizotinib can cause dose-dependent QTc interval prolongation, which can lead to serious and potentially fatal arrhythmias. An electrocardiogram (ECG) and electrolyte monitoring (potassium, magnesium, calcium) should be performed at baseline and periodically during treatment, especially in patients with pre-existing cardiac conditions or those taking concomitant medications known to prolong the QTc interval. Additionally, severe visual loss, including permanent vision loss, has been reported. Patients should undergo ophthalmological evaluations at baseline and promptly report any new or worsening visual symptoms, such as blurred vision, double vision, or flashes of light, to their doctor.

Frequently Asked Questions About Crizotinib

What should I tell my doctor before starting Crizotinib?

Before starting Crizotinib, inform your doctor about all your medical conditions, especially any history of liver problems, heart conditions (including irregular heartbeats or a family history of long QT syndrome), lung issues, or kidney disease. Disclose all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements, as Crizotinib can interact with many substances. Also, inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding, as Crizotinib can harm an unborn baby and is not recommended during breastfeeding.

How long will I need to take Crizotinib?

The duration of Crizotinib treatment varies for each patient and depends on several factors, including the cancer’s response to the medication, the tolerability of side effects, and the overall health of the individual. Patients typically continue taking Crizotinib for as long as it remains effective in controlling their cancer and the side effects are manageable. Your oncologist will regularly assess your condition through imaging scans and blood tests to determine the ongoing benefit of the treatment and make decisions regarding its continuation.

Can Crizotinib interact with other medications?

Yes, Crizotinib can interact with numerous other medications, which can either increase its side effects or reduce its effectiveness. It is metabolized by the CYP3A4 enzyme, so strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase Crizotinib levels, while strong CYP3A4 inducers (e.g., rifampin, phenytoin) can decrease its levels. Crizotinib also inhibits CYP3A4, potentially increasing the levels of co-administered drugs like midazolam or simvastatin. Always provide a complete list of all your medications to your healthcare provider to avoid potentially harmful drug interactions.